The latest 4C indicates an increasing sales, if compared with the 4C for the sale period last year there is a substantial increase in sales , but expenses seem to increase at the same rate, this is not how it is works for pharmaceuticals - normally when a patient begins on a treatment the patient stays on the medication for a reasonable length of time . Insulin for diabetes the patient is likely to require increasing doses. Advertising or promotion investment is not required to keep the patient on treatment.
Re -reading the announcements Bioton wan't to sell SIE no doubt the Chinese will buy SIE for it access to Insulin already selling in the Chinese market
The only question is : What price will the minority shareholders be offered?
- Forums
- ASX - By Stock
- Ann: Letter to Shareholders
The latest 4C indicates an increasing sales, if compared with...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)